Targeted androgen pathway suppression in localized prostate cancer: a pilot study.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 32, Issue 3, p.229-37 (2014)


2013, Center-Authored Paper, Clinical Research Division, Experimental Histopathology Core Facility, January 2014, Public Health Sciences Division, Research Trials Office Core Facility - Biostatistics Service, Scientific Imaging Core Facility


Ligand-mediated activation of the androgen receptor (AR) is critical for prostate cancer (PCa) survival and proliferation. The failure to completely ablate tissue androgens may limit suppression of PCa growth. We evaluated combinations of CYP17A and 5-α-reductase inhibitors for reducing prostate androgen levels, AR signaling, and PCa volumes.